aTyr Pharma, Inc. (ATYR) earnings · next report Nov 5, 2026
Next report
Thu, Nov 5, 2026
After the close · Tomorrow
Quarter ended Sep 2026
- EPS consensus
- −$4.40 Range −$4.80 – −$3.207 analystsYear ago −$10.40
- Revenue consensus
- $0 Range $0 – $08 analysts
EPS estimate trend
- 90 days ago−$5.33
- 60 days ago−$5.65
- 30 days ago−$4.00
- 7 days ago−$4.00
- Now−$4.00
Consensus +25.0% over 90 days. Last 30 days: 4 up, 0 down revisions.
Date and consensus: EODHD earnings calendar and estimates, refreshed every 6 hours. “Confirmed” means the provider lists the report session, which it sets once the company announces; “Estimated” is the provider’s expected date.
Follow ATYR into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in (Nov 5)
- — No options snapshot for this report yet (taken daily in the 7 days before a report, for stocks with listed options).
- Average move after earnings
- ±8.7% Absolute close-to-close move, 1 report
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
−$0.11
vs −$0.15 est. +26.7%
GAAP diluted EPS, SEC 10-Q
Revenue
—
No revenue consensus stored
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Beat EPS 2 quarters in a row
- Beat EPS in 2 of 4
- Aug 7, 2026BeatEPS −$0.11GAAP vs −$0.15 +26.7%Rev — vs —
- May 13, 2026BeatEPS −$0.11GAAP vs −$0.14 +22.8%Rev — vs —
- Nov 6, 2025MissEPS −$0.26GAAP vs −$0.18 −44.4%Rev $190.00K vs —
- Aug 7, 2025MissEPS −$0.22GAAP vs −$0.18 −22.2%Rev $0 vs —
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Jun 2026 | −$0.15 | −$0.11GAAP | +26.7% | — | — | — |
| May 13, 2026 | Mar 2026 | −$0.14 | −$0.11GAAP | +22.8% | — | — | — |
| Nov 6, 2025 | Sep 2025 | −$0.18 | −$0.26GAAP | −44.4% | — | $190.00KSEC | — |
| Aug 7, 2025 | Jun 2025 | −$0.18 | −$0.22GAAP | −22.2% | — | $0SEC | — |
Earnings documents
No earnings 8-K (item 2.02) is stored for this report yet. All ATYR filings: SEC filings.
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Healthcare peers with similar quant ratings
ATYR among 532 rated Healthcare stocks (Lician quant rating, Nov 4, 2026). How the rating works
- QTTB earnings5.00 · Strong Buy · stock
- AVAH earnings4.99 · Strong Buy · stock
- CDNA earnings4.98 · Strong Buy · stock
- HALO earnings4.97 · Strong Buy · stock
- OSCR earnings4.97 · Strong Buy · stock
- REGN earnings4.95 · Strong Buy · stock
- CON earnings4.94 · Strong Buy · stock
- PACS earnings4.94 · Strong Buy · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | — | −$0.11 | — |
| Q1 FY26 | — | −$0.11 | — |
| Q3 FY25 | $190.00K | −$0.26 | — |
| Q2 FY25 | — | −$0.22 | — |
aTyr Pharma, Inc. (ATYR) is a biotechnology company listed on US.
Latest reported ATYR revenue for 2025-12-31 was $190.0K. Net income was -$74.1M. Revenue was down 19.1% from 2024-12-31 to 2025-12-31. ATYR currently screens at market cap $471.7M.
When the next ATYR 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was down 19.1% from 2024-12-31 to 2025-12-31. An earnings headline that ignores that move is noise.
Not investment advice. Full ATYR research stays on the stock page; the tape stays on the quote page.
ATYR earnings FAQ
When is ATYR's next earnings date?
aTyr Pharma, Inc. (ATYR) is expected to report on Thu, Nov 5, 2026, after the close. The provider lists the session, which it sets once the company announces. Consensus EPS is −$4.40.
Did ATYR beat earnings estimates last quarter?
Yes. On Aug 7, 2026 aTyr Pharma, Inc. (ATYR) reported adjusted EPS of −$0.11 against a −$0.15 consensus (+26.7%), a beat.
How often does ATYR beat EPS estimates?
aTyr Pharma, Inc. (ATYR) beat the EPS consensus in 5 of its last 8 reported quarters.
What are ATYR's latest revenue and net income?
Latest cached aTyr Pharma, Inc. (ATYR) revenue for Dec 31, 2025 was $190.0K. Net income was -$74.1M. Statements: https://lician.com/financials/atyr
What is ATYR's latest diluted EPS?
Latest cached aTyr Pharma, Inc. (ATYR) diluted EPS for Dec 31, 2025 was -$0.80.
What period does the latest ATYR earnings print cover?
The latest cached aTyr Pharma, Inc. (ATYR) earnings print covers Dec 31, 2025. The prior cached period on this page is Dec 31, 2024.
How did ATYR revenue change from the prior cached period?
Cached aTyr Pharma, Inc. (ATYR) revenue was down 19.1% from $235.0K (Dec 31, 2024) to $190.0K (Dec 31, 2025). Statements: https://lician.com/financials/atyr
Where are ATYR earnings listed?
Cached earnings facts for aTyr Pharma, Inc. (ATYR) are listed at https://lician.com/earnings/atyr. Statements: https://lician.com/financials/atyr
Not investment advice.